Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

Ittai B. Muller; Adrianus J. De Langen; Richard J. Honeywell; Elisa Giovannetti; Godefridus J. Peters

doi:10.1586/14737140.2016.1131612

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

Ittai B. Muller, Adrianus J. De Langen, Richard J. Honeywell, Elisa Giovannetti, Godefridus J. Peters

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	147-157
Journal	Expert Review of Anticancer Therapy
Volume	16
Issue number	2
DOIs	https://doi.org/10.1586/14737140.2016.1131612
Publication status	Published - 1 Feb 2016

Access to Document

10.1586/14737140.2016.1131612

Cite this

@article{0775da24c61743c7a6172dddccaf806b,

title = "Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib",

keywords = "resistance mutation. EML-ALK, anaplastic lymphoma kinase, ceritinib, Acquired resistance, tyrosine kinase inhibitors, crizotinib",

author = "Muller, {Ittai B.} and {De Langen}, {Adrianus J.} and Honeywell, {Richard J.} and Elisa Giovannetti and Peters, {Godefridus J.}",

year = "2016",

month = feb,

day = "1",

doi = "10.1586/14737140.2016.1131612",

language = "English",

volume = "16",

pages = "147--157",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

AU - Muller, Ittai B.

AU - De Langen, Adrianus J.

AU - Honeywell, Richard J.

AU - Giovannetti, Elisa

AU - Peters, Godefridus J.

PY - 2016/2/1

Y1 - 2016/2/1

KW - resistance mutation. EML-ALK

KW - anaplastic lymphoma kinase

KW - ceritinib

KW - Acquired resistance

KW - tyrosine kinase inhibitors

KW - crizotinib

U2 - 10.1586/14737140.2016.1131612

DO - 10.1586/14737140.2016.1131612

M3 - Article

C2 - 26654422

VL - 16

SP - 147

EP - 157

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 2

ER -